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An abnormal number of chromosomes, or aneu-
ploidy, accounts for most spontaneous abortions,
causes developmental defects, and is associated
with aging and cancer. The molecular mechanisms
by which aneuploidy disrupts cellular function
remain largely unknown. Here, we show that aneu-
ploidy disrupts themorphology of the nucleus. Muta-
tions that increase the levels of long-chain bases
suppress nuclear abnormalities of aneuploid yeast
independent of karyotype identity. Quantitative lipi-
domics indicates that long-chain bases are integral
components of the nuclear membrane in yeast. Cells
isolated from patients with Down syndrome also
show that abnormal nuclear morphologies and in-
creases in long-chain bases not only suppress these
abnormalities but also improve their fitness. We ob-
tained similar results with cells isolated from patients
with Patau or Edward syndrome, indicating that
increases in long-chain bases improve the fitness
of aneuploid cells in yeast and humans. Targeting
lipid biosynthesis pathways represents an important
strategy to suppress nuclear abnormalities in aneu-
ploidy-associated diseases.INTRODUCTION
The incidence of aneuploidy in human germ cells increases with
age, leading to a higher risk of spontaneous abortions, stillbirths,
and infants born with chromosomal abnormalities, including
trisomies for chromosomes 13, 18, or 21, which cause Patau,
Edward, or Down syndrome, respectively (Edwards et al., 1960;
Lejeune et al., 1959; Nagaoka et al., 2012; Patau et al., 1960).
Among these, only patientswithDown syndrome live to adulthood
but showcognitive disabilities and several pathological conditions
associated with premature aging (Antonarakis, 2017). About 1 outCell Repor
This is an open access article under the CC BY-Nof every 700 babies are born with Down syndrome each year,
making this syndrome the most common genetic disease among
humans (https://www.cdc.gov). While it is thought that pathol-
ogies associated with Down syndrome are driven by the expres-
sion and activity of genes present on chromosome 21, it has
proven difficult to show that an extra copy of a specific gene is
solely responsible for a given phenotype in patients with Down
syndrome (Antonarakis, 2017). An alternative, yet not mutually
exclusive, hypothesis is that cellular defects associated with tri-
somy 21may be caused by the disruption of cellular homeostasis
due to the presence of the extra chromosome, that is, the
aneuploid status of the cell. However, cellular defects in human
trisomies driven by the presence of the extra chromosome inde-
pendent of the genes encoded within it remain unknown. Thus,
strategies to ameliorate clinical symptoms in patients with Down
syndrome associated with aneuploidy do not exist.
To study the physiological consequences of aneuploidy at the
cellular level, we generated a series of isogenic yeast strains,
each harboring an extra copy of a different chromosome (called
disomes) (Torres et al., 2007). Previous studies revealed several
aneuploidy-associated phenotypes in the disomes independent
of the identity of the extra chromosome (Dephoure et al., 2014;
Sheltzer et al., 2011; Torres et al., 2007, 2010). These include
lowered viability, altered metabolism, genomic instability, and
loss of protein homeostasis. Importantly, these phenotypes are
also present in aneuploid human cell lines and trisomic mouse
embryonic fibroblasts (MEFs), indicating that the cellular re-
sponses to aneuploidy are conserved in yeast and humans (Don-
nelly et al., 2014; Passerini et al., 2016; Santaguida et al., 2015;
Stingele et al., 2013; Williams et al., 2008). Loss of protein
homeostasis is mainly driven by the mRNA expression of the
genes present on the extra chromosomes, which in turn leads
to increased protein synthesis, folding, and turnover. In support
of this hypothesis, aneuploid cells are sensitive to drugs that
inhibit protein degradation pathways. However, increasing pro-
tein degradation by the loss of the deubiquitinating enzyme
UBP6 improves the fitness of aneuploid yeast cells independent
of the identity of the extra chromosome (Dephoure et al., 2014).
Thus, targeting protein degradation pathways is a strategy to
specifically affect the fitness of aneuploid cells.ts 29, 2473–2488, November 19, 2019 ª 2019 The Author(s). 2473
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Aneuploidy is thought to affect cellular metabolism due to
the synthesis of biomolecules and energy demands associated
with increased protein synthesis. Aneuploid yeast cells show
increased glucose utilization and strictly rely on the biosynthesis
of the amino acid serine, a key molecule that is used for the syn-
thesis of nucleotides, proteins, and lipids (Hwang et al., 2017;
Torres et al., 2007). Although the metabolic requirements of hu-
man trisomies are not well characterized, a conserved metabolic
pathway that is affected by aneuploidy in both yeast andmamma-
lian cells is the biosynthesis of sphingolipids (Hwang et al., 2017;
Tang et al., 2017). Aneuploid yeast, trisomicMEFs, and aneuploid
colon cancer cells show dysregulation of sphingolipid synthesis
and are sensitive to drugs that lead to the accumulation of ceram-
ides. Importantly, the physiological consequences or cellular pro-
cesses affected by altered sphingolipid levels in aneuploid yeast
cells, MEFs, or cancer cells are not understood.
Themechanisms that cause lower viability or genomic instability
in aneuploid cells are also not well understood. Furthermore, how
the presenceof an extra chromosomeaffects organelle function in
yeast or human cells has not been studied. Here we found that
aneuploidy disrupts nuclear integrity in yeast and primary fibro-
blasts from patients with Patau, Edward, or Down syndrome.
Remarkably, impairing ceramide synthesis, which leads to the
accumulation of long-chain bases, improves fitness and sup-
presses nuclear abnormalities in both aneuploid yeast and human
cells. Our results indicate that long-chain bases are integral struc-
tural components of the nuclear membrane and their levels are
important in maintaining nuclear integrity. Because abnormal nu-
clear morphology is a hallmark of aging, the discovery that the
presence of an extra chromosome disrupts nuclear morphology
raises the hypothesis that aneuploidy drives pathologies associ-
ated with premature aging in patients with Down syndrome.
RESULTS
Aneuploidy Disrupts Nuclear Morphology in Yeast
The effects of aneuploidy on the morphology and integrity of the
nucleus have not been studied. We previously showed that the
volume of the cell increases in the disomes and that these in-
creases correlate with the size of the extra chromosome (Torres
et al., 2007). These results raise the possibility that the volume of
the nucleus is also affected by the presence of an extra chromo-
some. To investigate this, we measured nuclear volumes in the
disomes by tagging the inner nuclear membrane protein Heh1
with GFP at its endogenous locus. Using live-cell microscopy,
we analyzed the surface area of nuclei by measuring the perim-
eter of the nucleus of wild-type cells and the disomes. We foundFigure 1. Aneuploidy Disrupts the Nuclear Morphology of Yeast
(A) Representative live-cell images of wild-type cells and 4 disomes expressing He
Differential interference contrast (DIC) microscopy is shown below. Scale bar, 5
(B) Histograms of the surface area of nuclei from aneuploid yeast strains compare
measurements of images from live-cell microscopy are shown (see STAR Metho
(C) Representative Coulter counter profiles of the diameters of purified nuclei fro
(D) Linear correlation of nuclear volumes measured using a Coulter counter and t
(E) Representative Coulter counter histograms of the diameters of wild-type cells
(F) Representative live-cell images of wild-type cells and 4 disomes showing abn
(G) Percentage of cells showing abnormal nuclear morphologies in aneuploid yethat the nuclei of the disomes display significant increases in sur-
face area compared with wild-type cells (Figures 1A and 1B).
These results indicate that the volume of the nucleus is affected
by the presence of an extra chromosome.
To validate these results, we isolated nuclei from yeast cells
and measured their volume in solution. Briefly, yeast cells were
lysed enzymatically, and nuclei were isolated in a sucrose
gradient and reconstituted in PBS (see STAR Methods). Of
note, we avoided the use of detergents, because they would un-
doubtedly interfere with the lipid composition and structure of
the nuclear membrane. Using a cell counter analyzer (Coulter
counter), we confirmed that nuclear volumes of yeast cells in-
crease by the presence of an extra chromosome (Figures 1C,
1D, and S1A). Interestingly, increases in nuclear volumes of the
disomes show a linear correlation with the number of genes
encoded in the extra chromosome (Figure 1D; R2 = 0.55).
Furthermore, nuclear volumes correlate with increases in cell
volume, indicating that the nuclear-to-cytoplasmic ratio of aneu-
ploid cells remained constant (Figures 1E and S1B).
Strikingly, during the analysis of nuclear volumes, we found
that the nuclear morphology of a substantial portion of the pop-
ulation in all aneuploid yeast strains was severely compromised
(from 5% in disome I to 53% in disome XV; Figures 1F, 1G, and
S1C). Whereas wild-type cells show round, smooth, and contin-
uous nuclear morphologies, the shape of the nucleus of the dis-
omes is highly irregular and discontinuous, indicating that the
presence of an extra chromosome disrupts the integrity of the
nuclear membrane. These results revealed that aneuploidy
causes defects in nuclear morphology independent of the iden-
tity of the extra chromosome. Furthermore, these data suggest
that abnormal nuclear morphology may contribute to several
cellular phenotypes associated with aneuploidy, including lower
viability, genomic instability, and shortened lifespan (Sheltzer
et al., 2011; Sunshine et al., 2016). Abnormal morphology of
the nucleus constitutes an aneuploidy-associated phenotype
that has not been previously described.
Interestingly, yeast cells that harbor yeast artificial chromo-
somes (YACs) containing heterochromatic human DNA show
minor increases in cell or nuclear volumes and show typical nu-
clear morphologies (Figure S1A). These results indicate that the
presence of extra DNA is not sufficient to disrupt the nucleus in
yeast cells.
Mutations that Elevate the Levels of LCBs Suppress
Nuclear Abnormalities of Aneuploid Yeasts
We previously identified mutations that improve the fitness
of aneuploid yeast cells irrespective of the identity of the extrah1 taggedwith GFP (Heh1-GFP) at its endogenous locus showing round nuclei.
mm.
d with wild-type cells (n = 200). Nuclear volumes calculated from surface area
ds).
m wild-type cells and 4 disomes (n = 30,000).
he number of open reading frames in the duplicated chromosomes (R2 = 0.55).
and 4 disomes (n = 30,000).
ormal nuclear morphology. DIC microscopy is shown below. Scale bar, 5 mm.
asts, shown as mean ± SD (n = 200, 3 biological replicates).
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Figure 2. Increasing the Levels of Long-Chain Bases Suppresses the Nuclear Abnormalities of Aneuploid Yeast
(A) Simplified schematic of the biochemical pathway of the synthesis of long-chain bases (LCBs) and ceramide.
(B) Quantitativemass spectrometry of the levels of LCBs and ceramides inwild-type cells and cells harboring lag1D (error bars represent SD, n = 3 samples). DHS,
dihydrosphingosine; PHS, phytosphingosine; DHS-P, phosphorylated DHS; PHS-P; phosphorylated PHS.
(C) Representative live-cell images of disomes XI, XIV, and XVI expressing Heh1-GFP and harboring lag1D. Scale bar, 10 mm.
(D) Comparison of nuclear abnormalities of disomes versus disomes harboring lag1D (n = 200 cells, *p < 0.01, unpaired two-tailed Student’s t test).chromosome (Torres et al., 2010). Among thesewere several mu-
tations in genes that regulate the biosynthesis of long-chain bases
(LCBs: DHS [dihydrosphingosine] and PHS [phytosphingosine],
also called sphingoid bases) and ceramide, keymolecules essen-
tial for viability and proliferation. One of the mutations that
improved the fitness of all aneuploid yeast strains analyzed was2476 Cell Reports 29, 2473–2488, November 19, 2019the loss of function of ceramide synthase LAG1 (Hwang et al.,
2017). Ceramide synthase converts LCBs into ceramides; there-
fore, lower enzymatic activity leads to the accumulation of LCBs
(Figure 2A). Using quantitative mass spectrometry, we first
confirmed that loss of LAG1minimally affects the levels of ceram-
ides while the levels of PHS increased by 7.1-fold in yeast cells
(3.9 pmol/106 cells in WT to 28.2 pmol/106 cells in lag1D; Fig-
ure 2B; Table S1). Ceramide levels remain mostly unchanged
due to the activity of LAC1, the other ceramide synthase paralog
in yeast. Consistently, deletion of both LAG1 and LAC1 causes
lethality in yeast.
Interestingly, transcriptional analyses revealed that higher LCB
levels in aneuploid cells result in the upregulation of a cluster of
genes associated with components of the nucleus (Hwang
et al., 2017). We therefore investigated whether the nuclear ab-
normalities we observed in aneuploid yeasts are affected by the
loss of LAG1. We found that irrespective of the identity of the ex-
tra chromosome, nuclear defects of aneuploid yeast strains are
significantly suppressed by lag1D (Figures 2C and 2D). These re-
sults indicate that increases in LCB levels improve the fitness of
aneuploid cells due to the suppression of nuclear abnormalities
and raise the possibility that changes in LCB levels upon the
loss of ceramide synthase accumulate in the nuclear membrane.
To validate these results, we analyzed nuclearmorphologies of
disomes harboring the deletion of sphingosine kinase LCB4
(lcb4D), which also significantly improves the fitness of aneuploid
yeasts independent of karyotype (Hwang et al., 2017). Thismuta-
tion raises LCB levels by impairing their phosphorylation, which is
required for their degradationby the lipid lyaseDPL1 (FigureS2A).
Consistently,we found that loss ofLCB4also suppresses nuclear
defects in the disomes (Figure S2B). Because lcb4D reduces
phosphorylated LCBs and does not affect ceramide levels, our
results indicate that increases in LCBs are responsible for
improving the fitness of aneuploid yeasts.
A third mutation in the sphingolipid pathway that improves the
fitness of the disomes independent of karyotype is the loss of
sphingosine-1-phosphate phosphatase, or LCB3. Loss of
LCB3 leads to increased levels of LCBs and their phosphory-
lated forms while minimally affecting ceramide levels. Consis-
tently, we found that loss of LCB3 also improves the nuclear
morphology of the disomes (Figure S2C). Although the loss of
the deubiquitinating enzymeUBP6 improves the fitness of aneu-
ploid strains by enhancing protein degradation, this mutation
does not suppress the nuclear abnormalities of aneuploid cells
(Figure S2D). These results indicate that suppression of nuclear
defects is specific to changes in the levels of LCBs and that the
mechanisms by which loss of UBP6 improve the fitness of aneu-
ploid cells are distinct. Indeed, changes in LCB levels show ad-
ditive effects with the loss of UBP6 to improve the fitness of
aneuploid cells (Hwang et al., 2017). Interestingly, we found
that while increasing LCB levels suppresses nuclear defects in
the disomes, these lipids do not affect the cell or nuclear volumes
of the disomes (Figures S2E and S2F). Our findings support the
hypothesis that increases in LCB levels play a critical role in
improving the integrity of the nuclear membrane in aneuploid
cells. Furthermore, they provide a mechanism by which different
mutations in the sphingolipid biosynthetic pathway, all of which
elevate LCB levels, improve the fitness of aneuploid cells inde-
pendent of the identity of the extra chromosome.
De Novo Synthesis of LCBs Is Required to Maintain
Nuclear Integrity in Yeast
Our results raise the possibility that the biosynthesis of LCBs
plays an essential role in maintaining nuclear morphology inyeast cells. To investigate this, we analyzed the effects of target-
ing the de novo synthesis of sphingolipids in wild-type cells.
Serine palmitoyltransferase (SPT), the first and rate-limiting
enzyme in the de novo synthesis of LCBs, consists of 2 essential
subunits, LCB1 and LCB2, and a third non-essential small regu-
latory subunit, TSC3 (Figure S2A). This complex localizes to the
nuclear envelope (NE) and the endoplasmic reticulum (ER) (Fig-
ure 3A). We found that inhibition of SPT by myriocin severely dis-
rupts the nuclear morphology of yeast cells and that these ef-
fects do not occur upon translation inhibition by rapamycin
(Figures 3B and 3C). Consistently, loss of TSC3, which impairs
SPT activity and lowers LCB levels, also disrupted nuclear
morphology and integrity (Figures 3D–3G and S3A–S3D). These
defects were significantly attenuated by the addition of exoge-
nous LCBs, indicating that impaired sphingolipid synthesis is
responsible for the nuclear abnormalities of tsc3D (Figures 3F
and 3G). Using electron microscopy, we found that the well-
defined double lipid bilayer that constitutes the nuclear mem-
brane in wild-type cells is significantly affected in cells harboring
tsc3D (Figures 3H and S3E). These results show that SPT activity
is necessary to maintain the integrity of the nuclear membrane in
yeast.
Next, we tested the effects of the addition of excess LCBs to
the growth medium on the morphology of the nucleus. Wild-
type cells cultured in medium containing high concentrations
of LCBs display deformed nuclei with significant membrane ex-
pansions (Figures 3I and 3J). However, excess ceramide did not
affect themorphology of yeast nuclei or suppress nuclear abnor-
malities of tsc3D (Figures 3F, 3G, 3I, and 3J). These results indi-
cate that the cellular levels of LCBs, not ceramides, play an
essential role in maintaining the morphology of the nucleus in
yeast. Thus, robust regulatory mechanisms must exist to main-
tain homeostatic levels of LCBs in the cell, because either
decreasing or increasing these levels can significantly affect
the morphology of the nucleus.
LCBs, Not Ceramides, Are Enriched in the Nuclear
Membrane
The results showing that the morphology of the nucleus is sensi-
tive to changes in LCB levels suggest that these lipids may play a
fundamental role in the integrity of the nuclear membrane. To
determine whether LCBs are integral components of the nuclear
membrane, we measured their levels in the nucleus using quan-
titative mass spectrometry. To this end, we purified nuclei
without detergents in a sucrose gradient. Using a particle
analyzer and microscopy, we confirmed that the nuclear prepa-
rations were homogeneous and did not include whole or broken
cells or cell debris (Figures 1C and 4A). Using the reticulon Rtn1
as a marker for the ER, we estimated that about 20% of the ER
membrane co-purified with the nuclei (Figure 4B). By comparing
the amounts of LCBs in nuclei versus whole cells, we found that
up to 50%of cellular LCBs localize to the nucleus (Figure 4C, and
2.3 of 4.6 pmol/106 cells; Table S1).
In comparison, only 4% of total ceramides are found in the nu-
cleus (Figure 4C, and 0.09 of 2.1 pmol/106 cells). These results
indicate that LCB levels are25-fold higher than ceramide levels
in the nucleus. Considering a nuclear volume of 6 fL, we estimate
the concentration of nuclear LCBs to be around 400 mM,Cell Reports 29, 2473–2488, November 19, 2019 2477
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Figure 3. De Novo Synthesis of Long-Chain Bases Is Essential for Nuclear Integrity in Yeast
(A) Representative images of cells expressing Lcb1, Lcb2, or Tsc3 tagged with GFP. Scale bar, 10 mm.
(B) Representative images of wild-type cells expressing Heh1-GFP treated with myriocin or rapamycin for 3 h. Scale bar, 10 mm.
(C) Percentage of abnormal nuclei of wild-type cells treated with myriocin or rapamycin (n = 200).
(D) Kinetics of the serine palmitoyltransferase (SPT) enzymatic activity in wild-type cells and tsc3D (see STAR Methods). Error bars represent SD (n = 3).
(E) Fold change of the levels in LCBs upon tsc3D compared with wild-type cells, shown as mean ± SD (n = 3 biological replicates).
(F) Representative live-cell images of tsc3D cells expressing Heh1-GFP alone or treated with PHS or ceramide for 3 h. Scale bar, 10 mm.
(G) Percentage of nuclear abnormalities of tsc3D upon PHS or ceramide treatment (n = 200 cells).
(H) Representative electron micrograph images of the nuclear envelope in wild-type yeast and cell harboring tsc3D. Scale bar, 500 nm; zoom scale bar, 100 nm.
(I) Representative images of wild-type cells expressing Heh1-GFP treated with DHS, PHS, or ceramide for 3 h. Scale bar, 5 mm.
(J) Percentage of abnormal nuclei in wild-type cells expressing Heh1-GFP treated with DHS, PHS, or ceramide (n = 200 cells).
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Figure 4. Long-Chain Bases, Not Ceramides, Are Enriched in the Yeast Nucleus
(A) Representative image of a purified nucleus from yeast cells. Scale bar, 2 mm.
(B) Western blots of the reticulon protein Rtn1 tagged with GFP. Nop1 is a nucleolar protein used for loading control.
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indicating that LCBs are abundant in the nuclear membrane.
Notably, global lipidomics did not reveal enrichment for any
other major class of lipids in the yeast nucleus (Figure 4D; Table
S2). Instead, it demonstrated that the nuclear levels of phospha-
tidylserine (PS) and phosphatidylcholine (PC) are significantly
lower than expected when compared with their levels in whole
cells. PS and PC constitute only 0.1% and 2.7% of the nuclear
lipids, respectively, compared with 10% or 24% of the cellular
lipids, respectively (Figure 4D). These results indicate that
LCBs are enriched in the nuclear membrane and that ceramides,
the products of ceramide synthase, an enzyme that localizes to
the NE and ER, are rapidly transported out of the nucleus.
Furthermore, our results support the hypothesis that the enrich-
ment of LCBs in the yeast nuclear membrane has an essential
structural role in maintaining membrane integrity.Mutations that Improve the Fitness of Aneuploid Cells
Increase the Levels of LCBs in the Nucleus
In addition to suppressing the nuclear defects of aneuploid cells,
loss of ceramide synthase extends the lifespan of yeast (D’mello
et al., 1994). Our results raise the possibility that lag1D could pro-
mote longevity by maintaining nuclear integrity due to elevated
levels of LCBs in the nuclear membrane. To investigate whether
lag1D affects the lipid composition of the nucleus, we performed
quantitative lipidomics of whole cells and purified nuclei
harboring lag1D. We found that most increases in the levels of
LCBs elicited by the loss of LAG1 accumulate in the nucleus (Fig-
ures 4E and S4A; Table S1). Nuclear DHS and PHS levels in-
crease 2.1- and 9.2-fold, respectively, in lag1D compared with
wild-type cells. In addition, we found that up to 65% of total
LCBs are in the nucleus in lag1D cells (19 of 29 pmol/106 cells).
As with total ceramides, the nuclear levels of ceramides aremini-
mally affected by the loss of LAG1 (Figures 4F and S4A).
Similar results were obtained when nuclear lipids were quan-
tified from cells harboring lcb4D (Figures 4E, 4F, and S4A).
Nuclear DHS and PHS levels increase 9.4- and 6.1-fold,
respectively, in lcb4D compared with wild-type cells, and up
to 88%of total LCBs are in the nucleus (15 of 17 pmol/106 cells).
Total or nuclear levels of ceramides are not significantly
affected by lcb4D (Figure 4F). Furthermore, global lipidome
analysis showed that neither the loss of LAG1 nor that of
LCB4 affects the nuclear levels of any other major class of lipids
(Figure S4B; Table S2). We conclude that these mutations in-
crease the levels of LCBs in the nucleus to ameliorate nuclear
defects associated with aneuploidy. In addition, these results
support the hypothesis that raising the levels of LCBs in the nu-(C) Levels of LCBs (DHS, PHS, DHS-P, and PHS-P) and ceramides (phytoceramid
blue bars) are shown as mean ± SD (n = 3).
(D) Global lipidomics of whole cells and purified nuclei in yeast. IPC, inositol-P-
diinositol-phosphorylceramide; CL, cardiolipin; DAG, diacylglycerol; PA, ph
PI, phosphatidylinositol; PS, phosphatidylserine; Erg, ergosterol. Means ± SD ar
(E) Levels of LCBs in lcb4D and lag1D cells and purified nuclei are shown as me
(F) Levels of ceramides in lcb4D or lag1D cells and purified nuclei are shown as
(G) Probability distribution of root-mean-square (average) nuclear envelope fluctu
distribution in subset), n = 75 for each cell type.
(H) Average root-mean-square nuclear envelope fluctuation size as a function of n
fluctuations are shown for comparison).
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harboring lag1D.
Global quantitative lipidomics showed that the levels of both
LCBs and ceramides are elevated in aneuploid yeasts compared
withwild-type cells (Hwang et al., 2017). Interestingly, increases in
LCB levels in aneuploid yeasts range from 1.2-fold in disome I to
2.5-fold in disome IV, raising the possibility that LCB levels are
altered in the nucleus of the disomes. Indeed, quantitative lipido-
mics of purified nuclei of 3 representative disomes revealed that
the increases in LCBs accumulate in the nucleus (Figure S4C).
Aneuploid cells rely on the increases’ synthesis of LCBs for
viability; however, these increases are not sufficient to completely
prevent their nuclear abnormalities. Loss of LAG1 or LCB4 im-
proves the fitness of aneuploid cells by further increasing nuclear
levels of LCBs without the toxic accumulation of ceramides.Higher Levels of LCBs Increase Nuclear Envelope
Fluctuations In Vivo
Because increases in LCBs do not affect the volume of the nu-
cleus, we decided to assess whether LCBs alter physical prop-
erties of the nuclear membrane in vivo. To this end, we used
an assay to measure NE fluctuations using high-resolution fluo-
rescencemicroscopy of live cells (Schreiner et al., 2015;Williams
et al., 2019). In short, to visualize the NE, we tagged Nup82 with
GFP at its endogenous locus in wild-type cells and cells
harboring lag1D. To quantitatively determine nuclear fluctua-
tions, we reconstructed a 3D contour of the NE, and using spher-
ical coordinates centered on the nucleus at each time point, each
NE fluctuation was defined as the difference between the radial
coordinate of the contour and its time-average radial value. The
frequency andmagnitude of the fluctuations were determined by
computing the root-mean-square fluctuation (RMSF). Compari-
son of the distribution of RMSF from a population of nuclei
over time clearly shows that nuclei from lag1D cells have larger
fluctuations compared with nuclei from wild-type cells (Fig-
ure 4G). Analysis of the angle at which these fluctuations take
place (using a polar coordinate system based on bright-field im-
aging and an axis defined by bisecting the cell volume centered
on the bud location) shows that loss of LAG1 increases NE fluc-
tuations throughout the nuclear membrane (Figure 4H). We ob-
tained similar results when we analyzed NE fluctuations of cells
harboring the lcb4 or lcb3 deletions, although lcb4D showed
smaller changes. These results indicate that all three mutants in-
crease NE fluctuations in yeast and support the hypothesis that
higher levels of LCBs in the nuclear membrane lead to increased
membrane dynamics. Increased NE fluctuations may reflecte and dihydroceramide) in whole yeast cells (left, black bars) and in nuclei (right,
ceramide; MIPC, mannosyl-inositol-phosphorylceramide; M(IP)2C, mannosyl-
osphatidic acid; PC, phosphatidylcholine; PE, phosphatidylethanolamine;
e shown (n = 3).
an ± SD (n = 3).
mean ± SD (n = 3).
ation sizes for wild-type, lcb3D, lcb4D, and lag1D cells (cumulative probability
uclear radial angle for the same population of cells (S. pombe nuclear envelope
higher membrane compliance that may help tolerate the pres-
ence of an extra chromosome in the nucleus of aneuploid cells.
De Novo Synthesis of LCBs Is Required to Maintain
Nuclear Integrity in Human Cells
The biochemical pathway of the de novo synthesis of LCBs and
ceramide is conserved from yeast to humans. Human SPT con-
sists of 2 subunits, SPTLC1 or SPTLC2/3, and a small subunit,
SPTSSA/B, to generate DHS (Figure S5A). Six human genes
encode for ceramide synthases, CerS1–CerS6. Expression of
each gene is restricted to different tissues, and their activities
are thought to confer specificity for lipid molecules of varying
length. Sphingosine, the other major LCBs in human cells, is
generated by the catabolism of ceramide by ceramidases. To
study the effects of changing LCB levels on the morphology of
the nucleus in human cells, we initially turned to hTERT-immor-
talized, non-transformed, human retinal pigment epithelial
(RPE-1) cells. These cells are mostly diploid and display homo-
geneous, smooth, and mostly circular or elliptical nuclear mor-
phologies (Figure 5A). Using immunofluorescence of lamin B1,
we found that the nuclear morphology of RPE-1 cells is severely
compromised upon SPT inhibition by myriocin (Figures 5A and
5B). Nuclei show abnormal morphologies and significant
decreases in volume upon myriocin treatment.
Next, we took a genetic approach and found that knockdown
of either of the main SPT subunits (SPTLC1 or SPTLC2) dramat-
ically affects nuclear morphology and decreases nuclear vol-
umes in RPE-1 cells (Figures 5C–5E). As observed in yeast, we
found that addition of exogenous LCBs to the growth medium
disrupts the morphology of the nucleus in RPE-1 cells, often
causing significant increases in volume without affecting karyo-
type, while ceramides have little effect (Figures 5F, 5G, and S5B).
Interestingly, sphingosine-1-phosphate (S1P) also affected the
nuclear morphology of RPE-1 cells, but to a lesser degree (Fig-
ures 5F and 5G). These results indicate that either lowering or
increasing the levels of LCBs affects the morphology of human
epithelial cells.
To validate these results, we performed similar experiments
with primary human skin fibroblasts isolated from apparently
healthy donors (Figures 5H–5K). Consistently, we found that
inhibition of SPT by myriocin or addition of excess LCBs to the
growth medium disrupts nuclear morphology of primary human
fibroblasts. Lastly, we obtained similar results with hTERT-
immortalized diploid human foreskin fibroblasts (Figures S5C
and S5D). Altogether, these results establish an essential role
for LCBs in maintaining the integrity of the nucleus in human
epithelial cells and fibroblasts.
Aneuploidy Disrupts Nuclear Morphology of Fibroblasts
Isolated from Patients with Down Syndrome
The cellular defects driven by aneuploidy in cells from patients
with Down syndrome are not known. Because most aneu-
ploidy-associated phenotypes discovered in yeast cells have
subsequently been shown to be present in human aneuploid
cells, we hypothesized that aneuploidy might disrupt nuclear
morphology in human cells trisomic for chromosome 21. To
investigate the effects of aneuploidy on the morphology of the
nucleus in human cells, we initially obtained early-passage pri-mary trisomy 21 fibroblasts from two independent donors with
Down syndrome (Coriell catalog numbers GM04616 and
GM04592) and fibroblasts from two euploid apparently healthy
individuals, hereafter called controls (GM00969 and GM08447).
To assess nuclear morphology, we cultured all cell lines using
standard tissue culture conditions and performed immunofluo-
rescence using an antibody against lamin B1. Remarkably, we
found that compared with controls, the nuclei of both trisomy
21 cell lines displayed abnormal nuclear morphologies (Fig-
ure 6A). While 98% of the nuclei from control fibroblasts show
a smooth circular or elliptical nuclear shapes, up to 60%of nuclei
from fibroblasts of patients with Down syndrome show irregular
and distorted shapes (Figures 6A–6C).
Interestingly, as seen in aneuploid yeast cells, we observe sig-
nificant phenotypic heterogeneity in nuclear morphologies
of trisomy 21 cells, with some cells showing normal morphol-
ogies (40%–50%), others showing a mildly affected nucleus
(abnormal, 40%–45%), and a third population showing dramatic
changes in nuclear morphology (severe, 15%–20%) (Figures 6A
and 6C). We hypothesize that this heterogeneity is associated
with the phenotypic variability and non-genetic individuality pre-
viously described as hallmarks of aneuploid cells (Beach et al.,
2017; Pavelka et al., 2010). Indeed, analyses of nuclear morphol-
ogies of fibroblasts from five other patients with Down syndrome
show abnormal nuclear morphologies to varying degrees inde-
pendent of the age or sex of the donor (Figure S6A). These
results indicate that the presence of an extra copy of chromo-
some 21 causes nuclear abnormalities in human fibroblasts
and supports the hypothesis that aneuploidy disrupts nuclear
morphology in yeast and humans.
An abnormal nuclear morphology is a hallmark of premature
aging (Scaffidi andMisteli, 2006). Because several clinical symp-
toms in patients with Down syndrome are associated with pre-
mature aging, we hypothesize that the nuclear morphology of
trisomy 21 fibroblasts may resemble nuclei of cells from patients
with progeroid syndromes. Therefore, we obtained primary fi-
broblasts from 2 patients with Hutchinson-Gilford progeria
syndrome (HGPS) through the Progeria Research Foundation
Cell and Tissue Bank (catalog numbers HGADFN167 and
HGADFN367). Analysis of nuclear morphologies revealed that
nuclei of trisomy 21 cells display abnormalities strikingly similar
to those observed in nuclei from fibroblasts of HGPS patients
(Figures S6B and S6C). Therefore, it is plausible that an abnormal
nuclear morphology is associated with premature aging pheno-
types of patients with Down syndrome.
Inhibition of Ceramide Synthase Suppresses Nuclear
Abnormalities of Fibroblasts from Patients with Down
Syndrome
Our findings showing that lag1D suppresses the nuclear abnor-
malities of aneuploid yeast raise the possibility that increasing
the levels of LCBsmay improve the nuclear defects of fibroblasts
from patients with Down syndrome. To investigate this, we
turned to fumonisin B1, a toxin that specifically inhibits ceramide
synthases. Using quantitative mass spectrometry, we first
confirmed that micromolar concentrations of fumonisin B1 cause
a significant increase in the levels of LCBs in human cells (Fig-
ure S6D; Table S3). Interestingly, DHS, not sphingosine, isCell Reports 29, 2473–2488, November 19, 2019 2481
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Figure 5. Long-Chain Bases Are Essential for Maintaining Nuclear Integrity in Human Cells
(A) Representative images of RPE-1 nuclei mock treated and treated with myriocin for 24 h. Immunofluorescence for lamin B1 is red, and the nucleus is blue
stained with Hoechst 33342.
(B) Percentage of nuclear abnormalities of RPE-1 cells treated with myriocin (n = 100 cells).
(C) Representative images of RPE-1 nuclei upon knockdown of SPTLC1 or SPTLC2 after 72 h.
(D) Percentage of nuclear abnormalities of RPE-1 cells upon knockdown of SPTLC1 or SPTLC2 (n = 100 cells).
(E) Western blot analysis of SPTLC1 and SPTLC2 protein levels in RPE-1 cells.
(F) Representative images of RPE-1 nuclei treated with DHS, sphingosine (Sph), sphingosine-1-phosphate (S1P), or ceramide (Cer) for 24 h.
(G) Percentage of RPE-1 cells showing abnormal nuclear morphology when treated with DHS, sphingosine (Sph), sphingosine-1-phosphate (S1P), or ceramide
(n = 100 cells).
(H) Representative images of primary human skin fibroblast (HSF) nuclei mock treated and treated with myriocin for 24 h.
(I) Percentage of nuclear abnormalities of primary HSF treated with myriocin (n = 100 cells).
(J) Representative images of primary HSF nuclei treated with DHS, sphingosine (Sph), sphingosine-1-phosphate (S1P), or ceramide for 24 h.
(K) Percentage of primary HSF showing abnormal nuclear morphology when treated with DHS, sphingosine (Sph), sphingosine-1-phosphate (S1P), or ceramide
(Cer) (n = 100 cells).
All images are representative of three biological replicates. Scale bars (A, C, F, H, and J), 10 mm.
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Figure 6. Long-Chain Bases Suppress Nuclear Abnormalities Associated with Aneuploidy in Human Cells
(A) Representative images of primary human fibroblasts from 2 euploid donors and 2 patients with Down syndrome. Immunofluorescence for lamin B1 is red, and
the nucleus is blue stained with Hoechst 33342. Scale bar, 2.5 mm.
(B) Percentage of fibroblasts from euploid donors showing abnormal nuclear morphology when treated with fumonisin B1 or SKi-II (n = 100).
(C) Percentage of fibroblasts from 2 patients with Down syndrome showing abnormal nuclear morphology treated with fumonisin B1, SKi-II, or ceramide (Cer)
(n = 100).
(D) Representative images of trisomy 21 nuclei treated with fumonisin B1, SKi-II, or ceramide. Scale bar, 10 mm.
(E) Representative images of primary human fibroblasts from 2 euploid donors and 2 patients with Patau syndrome (trisomy 13) or Edward syndrome (trisomy 18).
Immunofluorescence for lamin B1 is red, and the nucleus is blue stained with Hoechst 33342. Scale bar, 2.5 mm.
(F) Percentage of fibroblasts from 2 patients with Patau syndrome showing abnormal nuclear morphology treated with fumonisin B1, SKi-II, or ceramide (n = 100).
(G) Percentage of fibroblasts from 2 patients with Edward syndrome showing abnormal nuclear morphology treated with fumonisin B1, Ski-II, or ceramide
(n = 100).
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Figure 7. Suppressing Aneuploidy-Associated Phenotypes Improves the Proliferation of Human Trisomies
(A) Representative images of primary human fibroblasts from euploid donors and patients with Patau syndrome (trisomy 13), Edward syndrome (trisomy 18), or
Down syndrome (trisomy 21). Immunofluorescence is shown for lamin A/C, H3K9triMe, and Hoechst 33342. In the merge images, lamin A/C is green, H3K9triMe
is red, and DNA is blue. Scale bar, 5 mm.
(legend continued on next page)
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elevated by fumonisin B1, indicating that this drug inhibits cer-
amide synthase activity associated with the de novo synthesis
pathway of LCBs.
Whereas fumonisin B1 minimally affected the nuclei of control
fibroblasts, it significantly suppressed the nuclear abnormalities
of fibroblasts from patients with Down syndrome (Figures 6B–
6D). To confirm that elevated levels of LCBs suppress the
nuclear abnormalities of trisomy 21 cells, we inhibited LCB
degradation by pharmacological inhibition of sphingosine ki-
nases. Consistently, we found that although control cells were
minimally affected, the nuclear abnormalities of trisomy 21 cells
are significantly suppressed upon treatment with the sphingo-
sine kinase inhibitor SKi-II (Figures 6B–6D). Notably, we found
that ceramide does not alter nuclear morphology and does not
improve the nuclear shape of trisomy 21 fibroblasts, indicating
that the effects are specific to changes in the levels of LCBs (Fig-
ures 6C and 6D). Next, we examined whether increasing LCB
levels suppressed the nuclear abnormalities of primary fibro-
blasts from patients with HGPS, which show abnormal nuclear
morphologies due to point mutations in lamin A. We found that
neither fumonisin B1 or SKi-II had an effect on the nucleus of
fibroblasts from patients with HGPS (Figures S6B and S6C).
Altogether, these results indicate that aneuploidy disrupts the
morphology of the nucleus due to insufficient levels of LCBs.
Consequently, increasing cellular levels of LCBs is beneficial to
cells from patients with Down syndrome, but not to those from
patients with other laminopathies.
Primary Fibroblasts Isolated from Patients with Edward
or Patau Syndrome Show Abnormal Nuclear
Morphologies
To determine whether abnormal nuclear morphologies of fibro-
blasts from patients with Down syndrome are specific to tri-
somy 21 or aneuploidy affects the morphology of human cells
independent of the identity of the extra chromosome, we
analyzed the nuclear morphologies of other human trisomies.
To this end, we obtained primary fibroblast cell lines from
two independent donors with Patau syndrome (trisomy 13,
GM00526 and GM02948) or Edward syndrome (trisomy 18,
GM00734 and GM03538). We found that the nuclei of these
cells show abnormal morphologies similar to those of cells
from patients with Down syndrome or HGPS. In both trisomies,
up to 60% of the cells show abnormal nuclear morphologies
(Figures 6E–6G). These results support the hypothesis that
the morphology of the nucleus is affected by aneuploidy, inde-
pendent of the identity of the extra chromosome, in yeast and
human. Furthermore, we found that either fumonisin B1 or SKi-II
suppressed the nuclear defects of trisomies 13 and 18,(B) Western blot analysis of H3K9triMe in human fibroblasts.
(C) Quantification of the number of 53BP1 foci in human fibroblasts mock treate
(D) Representative images of primary human fibroblasts from euploid donors and
and Hoechst 33342 (blue). There is no correlation between abnormal nuclear mo
(E) Growth curves of primary human fibroblasts from 2 euploid donors and 2 patien
with increasing concentrations of fumonisin B1.
(F) Representative images of primary human astrocytes from 4 euploid donors an
stained with Hoechst 33342. Scale bar, 5 mm.
(G) Percentage of astrocytes from euploid and trisomy 21 donors showing abnowhereas ceramides had little effect. These results provide
strong evidence that increasing LCB levels suppresses nuclear
abnormalities of aneuploid human cells independent of the
abnormal karyotype.
To investigate whether the acquisition of an extra copy of a
given chromosome affects the nucleus in human cells, we
analyzed the nuclear morphology of a series of human trisomic
cell lines constructed by micronuclei-mediated chromosome
transfer into RPE-1 cells (Stingele et al., 2012). As observed in
primary fibroblasts, we found that up to 40% of the RPE-1 cells
harboring extra copies of chromosome 7 (RPE-1 7/3), chromo-
some 8 (RPE-1 8/3), or chromosome 21 (RPE-1 21/3) also
display abnormal nuclei compared with their control counter-
parts (Figures S6E and S6F). These results show that trisomy
in human cells affects the morphology of the nucleus in primary
fibroblasts and immortalized epithelial cell lines.
Increases in LCB Levels Improve the Fitness of Human
Aneuploid Cells
To gain insight into the physiological consequences of harboring
a nucleus with abnormal morphology, we initially assessed
whether the association between NE and chromatin was
affected in aneuploid cells. Using immunofluorescence, we
found that the levels of the tri-methylation of lysine 9 of histone
H3 (H3K9triMe), an established marker of lamina-associated
domains, were heterogeneous in control primary human fibro-
blasts. The levels of this histone mark varied from no signal to in-
termediate to high levels in the nuclei of control fibroblasts (Fig-
ure 7A). Notably, we found that this heterogeneity was also
present in trisomy 21 fibroblasts, because nuclei with abnormal
morphologies show varying levels of H3K9triMe. These results
indicate that the levels of this histone mark do not correlate
with altered nuclear morphology (Figure 7A). We obtained similar
results when we assessed the levels of H3K9triMe of fibroblasts
trisomic for chromosomes 13 or 18 (Figure 7A). Consistently,
global analysis of H3K9triMe by western blots showed no
significant changes between control and trisomic fibroblasts
(Figure 7B).
Aneuploid cells show increased signs of replication stress as-
sessed by the number of 53BP1 foci (Santaguida et al., 2017).
Indeed, analysis of the number of 53BP1 foci revealed that hu-
man trisomies 21, 18, and 13 show increased replication stress
when compared with controls (Figure 7C). However, the number
of foci did not correlate with nuclear abnormalities in the aneu-
ploid cells. Furthermore, the number of 53BP1 foci did not
change when cells were grown in the presence of fumonisin B1
(Figure 7D). These data confirm that trisomy 21 fibroblasts
show increased signs of replication stress; however, thered or in the presence of fumonisin B1 (n = 100).
patients with Down syndrome. Immunofluorescence is shown for 53BP1 (red)
rphology and number of 53BP1 foci. Scale bar, 5 mm.
ts with Patau (trisomy 13), Edward (trisomy 18), or Down syndrome (trisomy 21)
d 4 donors with Down syndrome. Immunofluorescence for the nucleus is blue
rmal nuclear morphology (n > 200).
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seems to be no direct functional connection between abnormal
nuclear morphology and 53BP1 foci.
To assess the physiological relevance of suppressing nuclear
abnormalities in cells from patients with Down, Edward, or Patau
syndrome, we measured the proliferation rates of cells treated
with fumonisin B1. In the absence of this drug, human trisomic
cells proliferate more slowly than control counterparts, support-
ing the hypothesis that aneuploidy hampers cell proliferation in
yeast and human cells. Remarkably, we found that although
fumonisin B1 minimally affected the proliferation of control cells,
it significantly improved the proliferation rates of all three human
trisomies independent of karyotype (Figure 7E). These results
indicate that abnormal nuclear morphologies are associated
with impaired proliferation, and targeting ceramide synthesis
represents an important strategy to suppress aneuploidy-driven
phenotypes in human cells.
Astrocytes Isolated from Down Syndrome Patients
Show Abnormal Nuclear Morphologies
In addition to fibroblasts, is the nuclear morphology of other cell
types affected by trisomy 21? To address this, we analyzed
the nuclear morphologies of primary astrocytes derived from
the fetal brain with Down syndrome (Busciglio et al., 2002; Hel-
guera et al., 2013). DNA staining revealed that the nuclear mor-
phologies of four independent primary astrocytes established
from brains with trisomy 21 are significantly affected when
compared with controls (Figures 7F and 7G). These results indi-
cate that the nuclear integrity of several cell types and tissues
might be affected by trisomy 21. Altogether, our results provide
an important paradigm for Down syndrome research to study
aneuploidy-driven cellular defects and discover novel ap-
proaches to improve their fitness.
DISCUSSION
Abnormal nuclear morphology is a hallmark of premature aging,
neurodegenerative diseases, and cancer (Frost et al., 2016; Liu
et al., 2012; Scaffidi and Misteli, 2006; Zink et al., 2004). The
shape of the nucleus also changes dramatically during senes-
cence and healthy aging (Campisi, 2013; Lopez-Otin et al.,
2013; Scaffidi and Misteli, 2006). However, the factors that
lead to an abnormal nuclear shape remain mostly unknown. Dur-
ing aging, cells not only accumulate thousands of mutations but
also show an increased frequency of chromosomal abnormal-
ities. The incidence of aneuploidy is strongly associated with
increased age, and studies in yeast showed that aneuploidy
shortens the lifespan. Our results lead to the hypothesis that
aneuploidy may promote aging by disrupting nuclear integrity.
Important insights into the aging process have come from
studies of human diseases associated with premature aging.
The identification of mutations in the lamin A/C gene LMNA as
a cause of HGPS was a significant breakthrough that led to the
development of effective therapies (Gordon et al., 2016). Silent
mutations in LMNA affect splicing, leading to the expression of
a dominant-negative truncated version of lamin named progerin.
Progerin accumulates at the inner nuclearmembrane and affects
the morphology and function of the NE. Interestingly, although
the genetic bases of HGPS and progeroid syndromes are entirely2486 Cell Reports 29, 2473–2488, November 19, 2019unrelated to trisomy 21 in Down syndrome, several clinical
symptoms are shared between these two conditions. These
include growth retardation, skeletal and craniofacial anomalies,
heart defects, abnormal skin, low muscle tone, gastrointestinal
issues, and lower immunity. Our studies show that early-pas-
sage human fibroblasts from patients with Down syndrome
show abnormal nuclei reminiscent to those from patients with
HGPS. Based on these results, we propose that aneuploidy
plays a causative role in the deterioration of cellular function dur-
ing healthy aging and that this process is accelerated in patients
with Down syndrome by the presence of the extra chromosome.
The risk of neurodegenerative diseases increases with age in
humans. Notably, patients with Down syndrome develop neuro-
degenerative diseases similar to Alzheimer’s disease, and most
develop dementia by the age of 60 years. Although there is a
strong association between increased incidence of aneuploidy
and neurodegenerative diseases, the molecular mechanisms
underlying this connection are not known. In addition to the
accumulation of protein plaques, a hallmark of the histopatholo-
gy of neurodegeneration is the disruption of nuclear morphology.
Affected neurons show abnormal nuclear shapes and altered
chromatin staining. Furthermore, pathologists use abnormal
nuclear characteristics to diagnose and stage several other hu-
man diseases, including cancer. The events causing disruption
of nuclear integrity in human disease are not well understood.
Our studies provide an optimal platform to determine the molec-
ular mechanisms by which aneuploidy disrupts the nucleus and
to discover novel approaches that ameliorate the aneuploidy-
associated phenotypes in several human diseases.
Our results indicate that a concomitant increase in the biosyn-
thesis of lipids has a critical role in helping cells tolerate the pres-
ence of an extra chromosome in the nucleus. We show that
increasing the levels of LCBs improves fitness and suppresses
nuclear abnormalities in human trisomies, indicating that these
lipids play an essential role in the integrity of the nuclear mem-
brane. In yeast, we were able to show that LCBs, not ceramides,
are enriched in the nuclear membrane. Previous studies showed
that both LCB and ceramide levels increase in aneuploid yeast,
trisomic MEFs, and aneuploid cancer cells (Hwang et al., 2017;
Tang et al., 2017). Lipidomics analysis confirmed that these
lipids also increased in primary fibroblasts isolated from patients
with Down, Patau, or Edward syndrome compared with controls
(Figure S7D). In response to aneuploidy, cells increase the levels
of LCBs, which presumably help maintain nuclear membrane
integrity. However, these increases are not sufficient to fully
tolerate the presence of an extra autosome and are accompa-
nied by increases in the levels of ceramides. Ceramide levels
are tightly coupled to the LCB synthesis, and at least in the
context of aneuploidy, a mechanism that prevents the accumu-
lation of ceramide, a lipid molecule associated with cell-cycle
arrest and apoptosis, does not seem to be engaged. A genetic
screen pointed to genemutations that do precisely this: increase
LCBs without further increases in ceramides. Remarkably,
increasing LCBs by either genetic or chemical approaches im-
proves fitness and suppresses nuclear abnormalities of aneu-
ploid cells in yeast and humans. Our findings also indicate that
in addition to functioning as signaling molecules, LCBs play an
essential structural role in the nucleus due to their unique
biophysical properties. LCBs are single-chain amphipathic mol-
ecules with propensities for tight packing and high curvature.
Thus, the link between LCB levels and nuclear integrity points to-
ward potential direct or indirect effects on the physiology of the
cell. Moreover, such implications open new avenues for studying
the long-known association between lifespan and sphingolipids.
Interestingly, immunofluorescence and western blot analysis
indicate that the cellular levels of lamin proteins are not affected
in human trisomic cells (Figures 6A, 6E, and S7A). Furthermore,
actin cables show typical staining in cells harboring nuclei with
abnormal morphology (Figure S7B). Interestingly, here we
show that extra DNA alone is not sufficient to disrupt nuclear
morphology. Yeast cells harboring YACs with human DNA and
fibroblasts from patients with triple X syndrome show normal
nuclear morphologies (Figure S7C). The amount of the DNA in-
creases in triple X syndrome (156.0 Mb) is more significant
than that of trisomies 21, 18, and 13 (46.7, 80.4, and 114.3 Mb,
respectively), yet patients with triple X syndrome show minor
clinical symptoms, with up to 90% of cases not diagnosed.
The extra chromosome X is silenced by Xist, supporting the hy-
pothesis that the presence of extra DNA is not as deleterious
to the physiology of the cell as gaining an extra autosome.
Thus, we hypothesize that the active autosome and increases
in the cellular machinery involved in chromatin regulation and
increased gene expression may disrupt the morphology of the
nucleus, perhaps by creating biophysical stress in the nuclear
membrane. In support of this hypothesis, we show in yeast
that mutations that suppress nuclear abnormalities increase
the fluctuations of the NE, which may represent increased mem-
brane compliance, helping the cell cope with the presence of the
extra chromosome.
Lastly, our work provides an important framework for Down
syndrome research. In addition to increased expression of the
genes located on chromosome 21, cells from patients with
Down syndrome are affected by aneuploidy, which disrupts
cellular homeostasis at several levels. We show in this paper
that targeting ceramide synthesis improves the fitness of aneu-
ploid cells, including primary fibroblasts isolated from patients
with Down syndrome. Interestingly, fumonisin B1 is a food
contaminant commonly present in our diet, and at low levels, it
seems to be well tolerated by humans. The potential to use fu-
monisin B1 or other strategies to suppress aneuploidy-associ-
ated phenotypes in patients with Down syndrome represents
an exciting area for future research.STAR+METHODS
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Anti-SPTLC1 antibody Abcam ab176706
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Donkey Anti-Mouse IgG H&L (Alexa Fluor 488) Abcam ab150105; RRID:AB_2732856
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Goat Anti Rabbit antibody BioRad 170-6515; RRID:AB_11125142
Goat Anti Mouse antibody BioRad 172-1011; RRID:AB_11125936
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Myriocin Sigma M1177
Sphinganine (DHS) Avanti Polar Lipids 860498P
Phytosphingosine (PHS) Avanti Polar Lipids 860499
C16-ceramide Avanti Polar Lipids 860516P
C18-ceramide Avanti Polar Lipids 860518P
Sphingosine (SPH) Cayman 10007907
Sphingosine-1-phosphate (S1P) Cayman 62570
Rapamycin Sigma R8781
Fumonisin B1 (FB1) Cayman 62580
Sphingosine Kinase inhibitor (SKi)-II Cayman 10009222
Latrunculin B1 Cayman 10010631
Fetal Bovine Serum (FBS) Sigma F2442
Penicillin/Streptomycin GIBCO 15140-122
Trypsin-EDT solution GIBCO 25200-056
Glutamine GIBCO A2916801
Immobilon-P PVDF membrane Millipore IPVH00010
Protease inhibitor cocktail tablets Roche 11836170001
L-[U-C14] serine PerkinElmer NEC286E050UC
EcoLite(+) Liquid Scintillation Cocktail MP Biomedicals 188247501
Zymolase USBiological Z1004
Glusulase PerkinElmer Z1000
Phalloidin-iFluor 488 Reagent Abcam ab176753
Hoechst 33342 Invitrogen H3570
Experimental Models: Cell Lines
Euploid human skin fibroblast (Control)_1 Coriell Institute GM00969; RRID:CVCL_7311
Euploid human skin fibroblast (Control)_2 Coriell Institute GM08447; RRID:CVCL_7487
Euploid human skin fibroblast (Control)_3 Coriell Institute GM05659; RRID:CVCL_7434
Euploid human skin fibroblast (Control)_4 Coriell Institute GM02036; RRID:CVCL_7348
Human Trisomy 13 fibroblast_1 Coriell Institute GM00526; RRID:CVCL_X075
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Human Trisomy 13 fibroblast_2 Coriell Institute GM02948; RRID:CVCL_X275
Human Trisomy 18 fibroblast_1 Coriell Institute GM00734; RRID:CVCL_X236
Human Trisomy 18 fibroblast_2 Coriell Institute GM03538; RRID:CVCL_X290
Human Trisomy 21 fibroblast_1 Coriell Institute GM04616; RRID:CVCL_V475
Human Trisomy 21 fibroblast_2 Coriell Institute GM04592; RRID:CVCL_V473
Human Trisomy 21 fibroblast_3 Coriell Institute AG05397; RRID:CVCL_L780
Human Trisomy 21 fibroblast_4 Coriell Institute AG06922; RRID:CVCL_X793
Human Trisomy 21 fibroblast_5 Coriell Institute GM02767; RRID:CVCL_V469
Human Trisomy 21 fibroblast_6 Coriell Institute AG08941; RRID:CVCL_X871
Human Trisomy 21 fibroblast_7 Coriell Institute AG08942; RRID:CVCL_X872
Human Triple X fibroblast_1 Coriell Institute GM00254; RRID:CVCL_7276
Human Triple X fibroblast_2 Coriell Institute GM04626; RRID:CVCL_X310
hTert-HFF Benanti and Galloway, 2004 N/A
RPE1 Stingele et al., 2012 N/A
RPE1-7/3 Stingele et al., 2012 N/A
RPE1-8/3 Stingele et al., 2012 N/A
RPE1-21/3 Stingele et al., 2012 N/A
HGPS fibroblasts from patient_1 The Progeria Research
Foundation (PRF) Cell
and Tissue Bank
HGADFN167; RRID:CVCL_1Y92
HGPS fibroblasts from patient_2 The Progeria Research
Foundation (PRF) Cell
and Tissue Bank
HGADFN367; RRID:CVCL_1Y99
Euploid human astrocyte (Control)_1 Helguera et al., 2013 N/A
Euploid human astrocyte (Control)_2 Helguera et al., 2013 N/A
Euploid human astrocyte (Control)_3 Helguera et al., 2013 N/A
Euploid human astrocyte (Control)_4 Helguera et al., 2013 N/A
Human Trisomy 21 astrocyte_1 Helguera et al., 2013 N/A
Human Trisomy 21 astrocyte_2 Helguera et al., 2013 N/A
Human Trisomy 21 astrocyte_3 Helguera et al., 2013 N/A
Human Trisomy 21 astrocyte_4 Helguera et al., 2013 N/A
Experimental Models: Organisms/Strains
S. cerevisiae: Strain background: W303: see Table S1 This paper This paper
S. pombe: cut11-GFP::ura4+ h+ ura4-D18 leu1-32 Schreiner et al., 2015 MKSP10
Recombinant DNA
pLKO.1:TRCN0000035010 targeting SPTLC1 Open Biosystems TRCN0000035010
pLKO.1:TRCN0000034973 targeting SPTLC2 Open Biosystems TRCN0000034973
pLKO.1-scramble Addgene #1864; RRID:Addgene_1864
pCMV-dR8.2 Addgene #12263
pMD2.G Addgene #12259; RRID:Addgene_12259
Software and Algorithms
Graphpad Prism 8.0 Graphpad https://www.graphpad.com/scientific-software/prism/
ImageJ NIH https://imagej.nih.gov/ij/index.htmlLEAD CONTACT AND MATERIALS AVAILABILITY
Reagents were obtained from commercial sources as indicated. This study did not generate new unique reagents. Further informa-
tion and requests for resources and reagents should be directed to andwill be fulfilled by the LeadContact, Eduardo Torres (eduardo.
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Yeast strains and growth conditions
All stains are derivatives of W303 (E187) and are listed below. All aneuploid strains used in this study were subjected to comparative
genomic hybridization (CGH) to ensure that the additional chromosome was present in its entirety. All deletions were first introduced
in wild-type cells by transformation and backcrossed into the disomes. One liter of synthetic medium (SM) consists of 1.7 g of yeast
nitrogen base without amino acids or ammonium sulfate, 4.8 g of ammonium sulfate, and 2 g of amino acid mix, which consist of
equal amounts of Ala, Arg, Asn, Asp, Cys, Gln, Glu, Gly, Iso, Leu, Lys, Met, Phe, Pro, Ser, Thr, Trp, Tyr, Val, adenine and uracil. Dupli-
cated chromosomes are marked with HIS3 and KanMX6 cassette and the presence of the extra chromosome is ensured by selection
in medium lacking His and the addition of kanamycin (200 mg/ml).
Culture of human cell lines
RPE1 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM; GIBCO) supplemented with 10% fetal bovine serum (FBS;
sigma) and 2 mM L-glutamine. Primary human skin fibroblasts (HSF) from young healthy individuals (GM08447, GM056659,
GM00969, and GM02036) and Trisomy fibroblasts (Trisomy 21: GM04616, GM04592, AG05397, AG06922, GM02767, AG08941,
and AG08942; Trisomy 13: GM00526 and GM02948; Trisomy 18: GM00734 and GM03538) were purchased from Coriell Cell Repos-
itories and used in passage between P6 to P15. They were grown in Minimum Essential Media (MEM; GIBCO) supplemented with
15% FBS and 2mM L-glutamine. The HGPS fibroblasts from patients (HGADFN167 and HGADFN367) and the control primary fibro-
blasts from healthy gender-matched parents (HGFDFN168 and HGMDFN368) were obtained from The Progeria Research Founda-
tion (PRF) Cell and Tissue Bank. These cells were grown in DMEM supplemented with 15% FBS and 2 mM L-glutamine and used in
passage between P6 to P10. hTert-HFF cell was kindly provided by Jennifer A. Benanti (Benanti and Galloway, 2004). The aneuploid
RPE1 cells generation and karyotypes are described in D€urrbaum et al. (2018).
Primary astrocytes
Primary human astrocytes cultures were established from four trisomy 21 (14 – 21 weeks of gestational age) and four age-matched
control (diploid) fetal cortical specimens. Sex information was not collected from the specimens. The protocols for tissue processing
complied with all federal and institutional guidelines. The cultures were maintained in DMEM supplemented with 10% FBS as
described in Helguera et al. (2013).
METHOD DETAILS
Live-cell microscopy of yeast cells
Cells grown at 25C in synthetic media were collected during early exponential phase (OD600 between 0.6 and 1.0) by centrifugation.
After washing cells with 1 X phosphate-buffered saline (PBS), they were put on slide glass, covered with glass and images were
immediately taken using Nikon Eclipse E400 microscope.
Quantification of nuclear volume from microscopy
Images were analyzed using imageJ software (https://imagej.nih.gov). Using the freehand tool the surface area (SA) of 200 non-
dividing nuclei was measured in pixels. The mean value was calculated by fitting the histogram to a normal distribution using the
GraphPad Prism 7 software. The volume was calculated assuming a perfect circle. Volume = 4/3*pi*r3 where r = sqrt (SA/pi). Pixels
were converted to mm using a scale bar of 10 mm (factor 10 = 60 pixels).
Volume quantification of purified nuclei using Coulter Counter
Yeast cells grown at 25C in synthetic media were collected during early exponential phase (OD between 0.6 and 1.0). 108 cells were
harvested and washed twice with water. Cells were lysed in 1 mL of lysis buffer (1.1 M sorbitol, 20 mM KCl, 0.5 mM MgCl2, pH 7.4)
with 50 mg/ml of zymolase and 10mMDTT for 1 hour at 30C. Spheroplasts were spun down at 2K rpm for 5 minutes, resuspended in
hypotonic solution (8%PVP, 10mMTris-HCl pH 6.4, 0.5mMMgCl2), and incubated for 10minutes at room temperature. Nuclei were
spun down at 2K rpm for 5 minutes and resuspended in PBS right before measuring their volume in a Coulter Counter (n = 30,000).
Quantification of abnormal nuclear morphology in yeast
To quantify the number of abnormal nuclei, 200 non-dividing cells expressing Heh1-GFP were analyzed by live-microscopy. Normal
nuclei which are always observed in wild-type cells show mostly circular, smooth and continuous GFP signal. Any nucleus that
showed deformed shape, broken nuclei, aggregated GFP signal, invaginations, membrane expansions or discontinuous GFP signal
was considered abnormal. Due to the heterogeneity and severity of the nuclear abnormalities of the aneuploid cells, we could not use
any software that would automatically quantify different geometrical parameters (e.g., circularity, sphericity index) of the shape of the
abnormal nuclei.
Electron microscopy of wild-type cells and cells harboring tsc3D was outsourced to the The Harvard Medical School EM Facility
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In vitro serine palmitoyltransferase assay
SPT activity was measured using methods described by Harmon et al. (2013) and R€utti et al. (2009). Briefly, 33 106 of exponentially
growing yeast cells were used for each assay. Cells were broken in 500 mL of cold 50 mM HEPES/NaOH (pH 8.1) and 1 mM EDTA
using French Press G-M. After removing cell debris by centrifugation at 10,000 x g for 5 minutes at 4C, the supernatant was spun at
100,000 x g in a TLA 120.2 (Beckman) rotor for 30 minutes at 4C to obtain microsomes. Microsomes were incubated in 200 ml of
reaction buffer containing 50 mM HEPES/NaOH (pH 8.1), 50 mM pyridoxy phosphate, 100 mM palmitoyl-CoA, 5 mM L-serine and
0.5 mM L-[U-C14] serine (50 mCi/ml) at 37C. C14-labeled lipids were extracted by addition of 0.5 mL of methanol/KOH: CHCl3
(4:1) with vortexing. After sequential additions of 0.5 mL of CHCl3, 0.5 mL of 0.2 mN NH4OH and 100 ml of 2 N NH4OH, mix them
and centrifuge at 12,000 x g for 1 min at room temperature. The lower phase (CHCl3) was washed twice with 0.9 mL of 0.2 mN
NH4OH and transferred in new tube. The CHCl3 was dried under N2 gas flow and resuspended in 5 mL of scintillation cocktail.
The radioactivity from the isolated lipids was determined by scintillation counter.
Yeast nuclear preparation for mass spectrometry
Diploid ofWT, lcb4D, lag1Dwith Nup82-GFP cells andWTwith Rtn1-GFPwere used for preparation of yeast nuclei. Themethods are
described in Schreiner et al. (2015). Briefly, exponentially growing yeast cells were taken and treatedwith 100mMof Tris-HCl (pH 9.4)
and 10mMDTT for 10minutes at 25C. After washing cells with enzyme buffer (1.1M sorbitol, 20mMof KCl, 0.5mMofMgCl2, pH 7.4
with NaOH), cells were incubated with 200 mg/mL of zymolase (MP biomedicals) and 100 mL of glusulase (PerkinElmer) in enzyme
buffer for 1 hour at 30C. Spheroplasts were applied on Ficoll-sorbitol cushion (7.5% of Ficoll and 1.1 M sorbitol) and centrifuged
at 10,000 x g for 15 minutes at 4C. After harvesting spheroplasts, cells were broken using Dounce homogenizer (Wheaton,
type B) in 8% Polyvinylpyrrolidone, 10 mM of Tris-HCl (pH 6.4), 0.5 mM of MgCl2 and proteinase inhibitor cocktail. Lysates were
loaded on three density step sucrose gradients (1.8, 2.3 and 2.5 M) and centrifuged at 15,000 x g for 1.5 hours at 4C. Nuclei
were harvested between 1.8 and 2.3 M sucrose gradient and then the number of nuclei were counted using a Coulter Counter
(Beckman).
Quantitative lipidomics of LCBs and ceramides
Mass spectrometry quantifications of long-chain bases and ceramides were outsourced to the Lipidomics Core Facility of the
Medical University of South Carolina. The methods are described in Bielawski et al. (2009). 108 yeast cells grown in SC media at
room temperature were harvested by centrifugation and frozen in liquid nitrogen before shipment in dry ice. Raw data of the total
lipid levels were divided by the number of cells measured using a Coulter Counter.
Global lipodomics of yeast nuclei
Quantification of the global lipid composition of purified nuclei were outsourced to Lipotype (https://www.lipotype.com). They use
quantitative shotgun lipidomic analysis previously described in Ejsing et al. (2009) and Klose et al. (2012). Briefly, samples weremixed
with 30 ml of internal lipid standard mixture, providing a total spike of 24 pmol DAG 17:0-17:0, 22 pmol PA 17:0-14:1, 41 pmol PE
17:0-14:1, 41 pmol PS 17:0-14:1, 42 pmol PC 17:0-14:1, 40 pmol PI 17:0-14:1, 14 pmol CL 15:0-15:0-15:0-16:1, 22 pmol ceramide
18:0;3/18:0;0, 37 pmol IPC 18:0;2/26:0;0, 36 pmol MIPC 18:0;2/26:0;0, 31 pmol M(IP)2C 18:0;2/26:0;0, and 57 pmol cholesterol-D7.
Samples were subsequently subjected to two-step lipid extraction (1 mL of solvent in each step) executed at 4C. The lower organic
phases were collected and evaporated in a vacuum evaporator at 4C. Lipid extracts were dissolved in 100 mL chloroform/methanol
(1:2; vol/vol) and analyzed by mass spectrometry using a LTQ Orbitrap XL (Thermo Fisher Scientific) equipped with a robotic nano-
flow ion source TriVersa NanoMate (Advion Biosciences). PA, PS, PE, PC, CL, PI, IPC, MIPC andM(IP)2C, DAG and lysolipid species
were monitored by negative ion mode FT MS analysis, whereas TAG and ceramide species were monitored by positive ion mode FT
MS analysis.
Nuclear envelope dynamics
S. cerevisiae of WT, lcb4D, lag1D with Nup82-GFP and S. pombe with Cut11-GFP were used for measuring nuclear envelope fluc-
tuations. Methods to quantify nuclear envelope fluctuations are described in detailed in Schreiner et al. (2015) and Williams et al.
(2019).
Nuclear staining of primary astrocytes
For nuclear staining, the cultures were fixed with 4% PFA and incubated with Hoechst 33342 (Molecular Probes). Fluorescence im-
ages were generated with Zeiss Axiovert 200 inverted microscope (objx63) and AxioVision Rel.4.8. software.
Immunofluorescence microscopy
Cells were fixed with 4% paraformaldehyde in 1X PBS for 10 minutes and permeabilized with 0.1% of Triton X-100 in 1X PBS for
8 minutes at room temperature. After blocking with 1% BSA and horse serum in 1X PBS for 1 hour at room temperature, cells
were incubated with 0.2 mg/mL of primary antibodies in 1X PBS for 2 hours at room temperature. Primary antibodies and
nuclei were visualized by donkey anti-mouse IgG H&L Alexa Fluor 488 (Abcam), donkey anti-rabbit IgG H&L Alexa Fluor568
(Abcam) and Hoechst 33342 (Invitrogen). Phalloidin-iFluor 488 Reagent (Abcam) was used for visualizing actin polymerization.e4 Cell Reports 29, 2473–2488.e1–e5, November 19, 2019
Then fluorescence signals were detected by LSM700 (Zeiss). A representative z-slice from the image stack was chosen for
figures.
Western blot assay
For yeast samples, same number of spheroplasts and nuclei was lysed with 1 X sample loading buffer (50 mM Tris-HCl pH 6.8, 2%
SDS, 100mM b-mercaptoethanol, 0.2%bromophenol blue) and heated on 95C for 10minutes. For human samples, cells were lysed
in lysis buffer (25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% SDS, and 0.5% deoxycholate with protease inhibitors).
Lysate was separated on SDS polyacrylamide gels, and then proteins were transferred onto a PVDF membrane and analyzed with
antibodies against GFP (Invitrogen), Nop1(Abcam), Lamin A/C (Abcam), Lamin B1 (Abcam), SPTLC1 (Abcam), SPTLC2 (Abcam),
Histone 3 (Abcam), H3K9triMe (Abcam), 53BP1 (Cell signal) and GAPDH (Millipore). Immunoreactive signals were detected by the
Super Signal reagent (Pierce).
QUANTIFICATION AND STATISTICAL ANALYSIS
Averages and standard deviations were calculated using Excel; error bars represent standard deviation of the average of 3 indepen-
dent experiments. Statistical significancewas defined by p values < 0.05 from an unpaired t test. Images were analyzed using imageJ
software (https://imagej.nih.gov). Using the freehand tool, the surface area (SA) of 200 non-dividing nuclei was measured in pixels.
The mean value was calculated by fitting the histogram to a normal distribution using the GraphPad Prism 7 software. Further infor-
mation for different experiments can be found in the figure legends.
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